Display options
Cite
Cohen JP, Felix A. Are payers treating orphan drugs differently?. J Mark Access Health Policy. 2014;2doi: 10.3402/jmahp.v2.23513.
Cohen, J. P., & Felix, A. (2014). Are payers treating orphan drugs differently?. Journal of market access & health policy, 2. https://doi.org/10.3402/jmahp.v2.23513
Cohen, Joshua P, and Felix, Abigail. "Are payers treating orphan drugs differently?." Journal of market access & health policy vol. 2 (2014). doi: https://doi.org/10.3402/jmahp.v2.23513
Cohen JP, Felix A. Are payers treating orphan drugs differently?. J Mark Access Health Policy. 2014 Jan 15;2. doi: 10.3402/jmahp.v2.23513. eCollection 2014. PMID: 27226840; PMCID: PMC4865792.
Copy Download .nbib Format: NLM
Share it on

J Mark Access Health Policy. 2014 Jan 15;2. doi: 10.3402/jmahp.v2.23513. eCollection 2014.

Are payers treating orphan drugs differently?.

Journal of market access & health policy

Joshua P Cohen, Abigail Felix

Affiliations

  1. Tufts Center for the Study of Drug Development, Boston, MA, USA.

PMID: 27226840 PMCID: PMC4865792 DOI: 10.3402/jmahp.v2.23513

Abstract

BACKGROUND: Some orphan drugs can cost hundreds of thousands of dollars annually per patient. As a result, payer sensitivity to the cost of orphan drugs is rising, particularly in light of increased numbers of new launches in recent years. In this article, we examine payer coverage in the United States, England and Wales, and the Netherlands of outpatient orphan drugs approved between 1983 and 2012, as well as the 11 most expensive orphan drugs.

METHODS: We collected data from drug regulatory agencies as well as payers and drug evaluation authorities.

RESULTS: We found that orphan drugs have more coverage restrictions than non-orphan drugs in all three jurisdictions. From an economic perspective, the fact that a drug is an orphan product or has a high per-unit price per se should not imply a special kind of evaluation by payers, or necessarily the imposition of more coverage restrictions.

CONCLUSION: Payers should consider the same set of decision criteria that they do with respect to non-orphan drugs: disease severity, availability of treatment alternatives, level of unmet medical need, and cost-effectiveness, criteria that justifiably may be taken into account and traded off against one another in prescribing and reimbursement decisions for orphan drugs.

Keywords: orphan drugs; pricing; reimbursement

References

  1. Orphanet J Rare Dis. 2012 Sep 26;7:74 - PubMed
  2. Health Aff (Millwood). 2013 Apr;32(4):762-70 - PubMed
  3. Eur J Health Econ. 2007 Sep;8(3):253-66 - PubMed
  4. J Manag Care Pharm. 2007 Nov-Dec;13(9):765-77 - PubMed
  5. Am Health Drug Benefits. 2010 Jan;3(1):15-23 - PubMed
  6. Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):133-9 - PubMed
  7. Ann Allergy Asthma Immunol. 2013 Feb;110(2):70-4 - PubMed
  8. Br J Clin Pharmacol. 2011 Apr;71(4):488-96 - PubMed
  9. Health Policy. 2011 Apr;100(1):25-34 - PubMed
  10. Hastings Cent Rep. 2012 Jan-Feb;42(1):27-34 - PubMed
  11. Orphanet J Rare Dis. 2011 Sep 27;6:62 - PubMed
  12. Pharmacoeconomics. 2011 Jan;29(1):63-82 - PubMed
  13. Orphanet J Rare Dis. 2008 Dec 16;3:33 - PubMed

Publication Types